India Says Homegrown MRNA COVID-19 Shot Safe In Early Trial

Author : Ajay Sinha | Published On : 14 Oct 2021

Indian pharmaceutical firm Gennova Biopharmaceuticals’ COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said
Government authorities have also approved further studies to test the vaccine’s efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India

Read more at https://fintechzoom.com/fintech_news_nasdaq-mrna/india-says-homegrown-mrna-covid-19-shot-safe-in-early-trial-3/